Freelite Serum Free Light Chain Assays
This site is for Healthcare Professionals only
Click here for Patient Information
Latest News Headlines
- More Hevylite™ kits launched28 July 2010
- 3rd Queen's Award for Binding Site01 July 2010
- New MININEPHPLUS™ with Freelite™ serum free light chain assays08 June 2010
- New Binding Site office in Belgium28 April 2010
- Binding Site sponsors 6th Serum Free Light Chain and Hevylite Symposium12 February 2010
- New screening algorithm with Freelite reduces labour-intensive IFE in Australian study21 January 2010
- Wikilite.com – a new online educational resource for Freelite™ and Hevylite™14 December 2009
- Simple and efficient initial diagnostic screen for monoclonal gammopathy using Freelite09 November 2009
- First Hevylite™ assays are available02 September 2009
Freelite is a major breakthrough for the detection and monitoring of Multiple Myeloma (MM) and other B-cell dyscrasia. There is now significant clinical evidence indicating the benefit of serum free light chain assays in initial screening for monoclonal gammopathies, identifying AL amyloidosis and Nonsecretory MM patients missed by conventional electrophoretic methods, as a prognostic indicator for progression in myeloma*, for risk stratification of MGUS patients* and rapid evaluation of treatment efficacy.
Freelite assays were developed by Binding Site to measure free lambda and free kappa immunoglobulin light chains. Our expertise in the manufacture of antibodies has enabled us to provide a quantifiable, highly specific, automatable free light chain assay for serum.
Review the clinical evidence for the utility of Freelite in detecting and monitoring plasma cell disorders and compare the results from laboratory protocols with and without Freelite.
* In the USA diagnostic use of this product is restricted to those stated in the product insert
Latest News 28 July 2010
More Hevylite™ kits launched
Binding Site launches four new products from their growing portfolio of Hevylite assays, a novel immunoassay panel designed for analysis of immunoglobulin heavy/light chain pairs. Like Freelite™ serum free light chain assays, Hevylite is CE marked for use in monitoring patients with Multiple Myeloma and other B cell dyscrasias.
- Hevylite IgA Kappa and Hevylite IgA Lambda are now available on Binding Site's specialist protein analyser, SPAPLUS™.
- Hevylite IgG Kappa and Hevylite IgG Lambda are also now available for the Siemens BN™II analyser.
- Results obtained using the Hevylite IgA Kappa and IgA Lambda assays for the Siemens BNII, launched in 2009, are already proving to be a clinically useful tool for monitoring these patients.
Hevylite is a panel of immunoassays using polyclonal antibodies targeted at unique junctional epitopes between heavy chain and light chain constant regions of intact immunoglobulins. The immunoassays can separately identify the different light chain types of each immunoglobulin class, i.e. IgAκ, IgAλ, IgGκ, IgGλ, IgMκ and IgMλ. These molecules are then measured in pairs, e.g. IgAκ/IgAλ, to produce ratios of monoclonal/background polyclonal immunoglobulin concentrations, in the same manner as serum free light chain κ/λ ratios (Freelite). These new automated assays offer increased sensitivity over serum protein electrophoresis for quantifying monoclonal immunoglobulins. More
